Contrasting Capstone Therapeutics (CAPS) & Its Competitors

Capstone Therapeutics (NASDAQ:CAPS) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its rivals? We will compare Capstone Therapeutics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.

Earnings & Valuation

This table compares Capstone Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Capstone Therapeutics	$43.38 million	-$2.56 million	-1.35
Capstone Therapeutics Competitors	$960.60 million	-$45.89 million	12.52

Capstone Therapeutics’ rivals have higher revenue, but lower earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

2.5% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Capstone Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	N/A	N/A	N/A
Capstone Therapeutics Competitors	-1,425.99%	-589.65%	-28.81%

Analyst Recommendations

This is a summary of recent ratings for Capstone Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1	0	0	0	1.00
Capstone Therapeutics Competitors	5780	12202	37654	1167	2.60

As a group, “MED – BIOMED/GENE” companies have a potential upside of 52.40%. Given Capstone Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Capstone Therapeutics has less favorable growth aspects than its rivals.

Volatility & Risk

Capstone Therapeutics has a beta of -0.83, suggesting that its stock price is 183% less volatile than the S&P 500. Comparatively, Capstone Therapeutics’ rivals have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.

Summary

Capstone Therapeutics rivals beat Capstone Therapeutics on 8 of the 13 factors compared.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.